{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:20:36Z","timestamp":1790785236936,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","nanomedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.nano.2016.01.021","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T03:15:21Z","timestamp":1457579721000},"page":"1185-1192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo"],"prefix":"10.1016","volume":"12","author":[{"given":"Bel\u00e9n","family":"Borrego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu\u00e9 D.","family":"Mota-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Almanza-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"de la Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily A.","family":"Burmistrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey N.","family":"Pestryakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bogdanchikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2016.01.021_bb0005","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1128\/JVI.02641-10","article-title":"Rift Valley fever: recent insights into pathogenesis and prevention","volume":"85","author":"Boshra","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.01.021_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2013.81","article-title":"The risk of Rift Valley fever virus introduction and establishment in the United States and European Union","volume":"2","author":"Rolin","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.nano.2016.01.021_bb0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.27.6.903","article-title":"Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice","volume":"27","author":"Kende","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nano.2016.01.021_bb0020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.nano.2016.01.021_bb0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"Peters","year":"1986","journal-title":"Antivir Res"},{"key":"10.1016\/j.nano.2016.01.021_bb0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.06.010","article-title":"Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome","volume":"109","author":"Lorenzo","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.nano.2016.01.021_bb0035","doi-asserted-by":"crossref","first-page":"S815","DOI":"10.1093\/clinids\/11.Supplement_4.S815","article-title":"Prevention of Rift Valley fever in Rhesus monkeys with interferon-\u03b1","volume":"11","author":"Morrill","year":"1989","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nano.2016.01.021_bb0040","first-page":"1","article-title":"Metal nanoparticles: the protective shield against virus infection","author":"Rai","year":"2014","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.nano.2016.01.021_bb0045","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2014.01.054","article-title":"Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections","volume":"35","author":"Lv","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2016.01.021_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2014.06.011","article-title":"Silver nanoparticles impair Peste des petits ruminants virus replication","volume":"190","author":"Khandelwal","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.nano.2016.01.021_bb0055","first-page":"309","article-title":"Silver nanoparticles","author":"Klippstein","year":"2010"},{"key":"10.1016\/j.nano.2016.01.021_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1134\/S1995078014010121","article-title":"Comparative evaluation of antimicrobial activity of silver nanoparticles","volume":"9","author":"Podkopaev","year":"2014","journal-title":"Nanotechnol Russia"},{"key":"10.1016\/j.nano.2016.01.021_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108876","article-title":"Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles","volume":"9","author":"Vazquez-Mu\u00f1oz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2016.01.021_bb0070","first-page":"117","article-title":"The treatment of the patients presenting with chronic inflammation of the trepanation cavity with a preparation containing silver nanoparticles following sanitation surgery of the open type","volume":"6","author":"Semenov","year":"2012","journal-title":"Vestn Otorinolaringol"},{"key":"10.1016\/j.nano.2016.01.021_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.32607\/20758251-2013-5-3-107-115","article-title":"Transfer of silver nanoparticles through the placenta and breast milk during in vivo experiments on rats","volume":"5","author":"Melnik","year":"2013","journal-title":"Acta Nat"},{"key":"10.1016\/j.nano.2016.01.021_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1134\/S1995078013030051","article-title":"Formation of certified reference materials and standard measurement guides for development of traceable measurements of mass fractions and sizes of nanoparticles in different media and biological matrixes on the basis of gamma-ray and optical spectroscopy","volume":"8","author":"Demin","year":"2013","journal-title":"Nanotechnol Russia"},{"key":"10.1016\/j.nano.2016.01.021_bb0085","first-page":"59","article-title":"Experimental models and instrumental studies for the assessment of risk in the hygiene and epidemiology","author":"Zaitseva","year":"2015","journal-title":"Health Risk Anal"},{"key":"10.1016\/j.nano.2016.01.021_bb0090","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(\u2212\/\u2212) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2016.01.021_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1477-3155-8-19","article-title":"Interaction of silver nanoparticles with Tacaribe virus","volume":"8","author":"Speshock","year":"2010","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2016.01.021_bb0100","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2147\/IJN.S53622","article-title":"Inhibition of A\/Human\/Hubei\/3\/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo","volume":"8","author":"Xiang","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2016.01.021_bb0105","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2016.01.021_bb0110","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1016\/j.vaccine.2011.04.043","article-title":"A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(\u2212\/\u2212) mice upon lethal virus challenge","volume":"29","author":"Boshra","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2016.01.021_bb0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1134\/S1995078014050061","article-title":"Silver-nanoparticle exposure on immune system of mice depending on the route of administration","volume":"9","author":"Kalmantaeva","year":"2014","journal-title":"Nanotechnol Russia"},{"key":"10.1016\/j.nano.2016.01.021_bb0120","doi-asserted-by":"crossref","first-page":"8894","DOI":"10.3390\/molecules16108894","article-title":"Silver nanoparticles as potential antiviral agents","volume":"16","author":"Galdiero","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2016.01.021_bb0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00000441-200206000-00004","article-title":"Viral agents as biological weapons and agents of bioterrorism","volume":"323","author":"Bronze","year":"2002","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.nano.2016.01.021_bb0130","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"Borio","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.nano.2016.01.021_bb0135","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jps.24001","article-title":"Silver nanoparticles: therapeutical uses, toxicity, and safety issues","volume":"103","author":"Dos Santos","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2016.01.021_bb0140","article-title":"Complex drug to prevent and treat intestinal infections","author":"Burmistrov","year":"2014","journal-title":"RU patent 2519659"},{"key":"10.1016\/j.nano.2016.01.021_bb0145","article-title":"Method of prevention and treatment of gastritis, stomach and duodenal ulcer","author":"Burmistrov","year":"2015","journal-title":"RU patent 2549975"},{"key":"10.1016\/j.nano.2016.01.021_bb0150","article-title":"Mean Argovit for treating the infected wounds","author":"Blagitko","year":"2005","journal-title":"RU patent 2245151"},{"key":"10.1016\/j.nano.2016.01.021_bb0155","article-title":"Method of treatment of ear, throat and nose diseases","author":"Voronzova","year":"2007","journal-title":"RU patent 2307657"},{"key":"10.1016\/j.nano.2016.01.021_bb0160","first-page":"4303","article-title":"Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza vitus type 3","volume":"8","author":"Gaikwad","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2016.01.021_bb0165","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.4238\/2014.March.19.2","article-title":"Inhibition effect of silver nanoparticles on herpes simplex virus 2","volume":"3","author":"Hu","year":"2014","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.nano.2016.01.021_bb0170","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1166\/jbn.2013.1659","article-title":"Silver nanoparticles inhibit vaccinia virus infection by preventing viral entry through a macropinocytosis-dependent mechanis","volume":"9","author":"Trefry","year":"2013","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.nano.2016.01.021_bb0175","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1021\/cr400714j","article-title":"(Intra)Cellular stability of inorganic nanoparticles: effects on cytotoxicity, particle functionality, and biomedical applications","volume":"115","author":"Soenen","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.nano.2016.01.021_bb0180","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1039\/c2cs15355f","article-title":"Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future","volume":"41","author":"Arvizo","year":"2012","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nano.2016.01.021_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2011.05.016","article-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","volume":"8","author":"Parveen","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2016.01.021_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jviromet.2012.03.014","article-title":"Rapid assessment of antiviral activity and cytotoxicity of silver nanoparticles using a novel application of the tetrazolium-based colorimetric assay","volume":"183","author":"Trefry","year":"2012","journal-title":"J Virol Methods"},{"key":"10.1016\/j.nano.2016.01.021_bb0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-3155-8-15","article-title":"PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture","volume":"8","author":"Lara","year":"2010","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2016.01.021_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-3155-8-1","article-title":"Mode of antiviral action of silver nanoparticles against HIV-1","volume":"8","author":"Lara","year":"2010","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2016.01.021_bb0205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1039\/C2EM30595J","article-title":"Silver nanoparticles in the environment","volume":"15","author":"Yu","year":"2013","journal-title":"Environ Sci Process Impacts"},{"key":"10.1016\/j.nano.2016.01.021_bb0210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3155-3-6","article-title":"Interaction of silver nanoparticles with HIV-1","volume":"3","author":"Elechiguerra","year":"2005","journal-title":"J Nanobiotechnol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963416000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T11:15:28Z","timestamp":1567682128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963416000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1549963416000927"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2016.01.021","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2016.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}